Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where James R. Neff is active.

Publication


Featured researches published by James R. Neff.


International Journal of Radiation Oncology Biology Physics | 1998

A MULTIDISCIPLINARY STUDY INVESTIGATING RADIOTHERAPY IN EWING'S SARCOMA: END RESULTS OF POG #8346

Sarah S. Donaldson; Margaret Torrey; Michael P. Link; Arvin S. Glicksman; Louis A. Gilula; Fran Laurie; John T. Manning; James R. Neff; William R. Reinus; Elizabeth I. Thompson; Jonathan J. Shuster

PURPOSE To determine if involved field radiation (IF) is equivalent to standard whole bone radiation (SF) in local tumor control; to establish patterns of failure following treatment; and to determine response, event-free survival (EFS), and overall survival rates from multidisciplinary therapy in Ewings sarcoma. METHODS AND MATERIALS Between 1983 and 1988, 184 children with Ewings sarcoma were enrolled onto Pediatric Oncology Group 8346 (POG 8346). A total of 178 (97%) met eligibility criteria; 6 had pathology other than Ewings sarcoma. Induction chemotherapy of cyclophosphamide/doxorubicin (adriamycin )(C/A) x 12 weeks was followed by local treatment either surgery or radiation therapy and C/A, dactinomycin, and vincristine for 50 weeks. Resection was advised for patients with small primary tumors if accomplished without functional loss. Forty patients were randomized to receive SF, whole bone radiation to 39.6 Gy plus a 16.2 Gy boost (total 55.8 Gy) or IF to 55.8 Gy, and the remainder were assigned to IF radiation. RESULTS Of 178 eligible patients, 141 (79%) had localized disease and 37 (21%) had metastases at presentation. Their 5-year EFS was 51% (SE 5%) and 23% (SE 7%) respectively. The response rate to induction chemotherapy was 88% (28% complete, 60% partial), but after radiotherapy the response rate increased to 98%. Thirty-seven of the localized patients underwent resection, of whom 16 (43%) required postoperative radiotherapy; the 5-year EFS of these surgical patients was 80% (SE 7%). The remaining 104 localized patients were eligible for randomization or assignment to receive radiotherapy; the 5-year EFS of these patients was 41% (SE 5%), with no significant difference in EFS between those randomized to SF vs. IF. Site of primary tumor correlated with 5-year EFS: distal extremity 65% (SE 8%), central 63% (SE 10%), proximal extremity 46% (SE 8%), and pelvic-sacral 24% (SE 10%) (p=0.004). Initial tumor size did not correlate significantly with EFS. Patterns of failure among the 141 localized patients revealed 23% of patients experienced a local failure, while 40% had a systemic failure. The 5-year local control rate for the surgical patients +/- postoperative radiotherapy was 88% (SE 6%), while for the patients undergoing radiotherapy alone it was 65% (SE 7%). There was no difference in local control between those randomized to SF vs. IF. The 5-year local control rate for the patients with pelvic-sacral tumors was 44% (SE 15%), significantly worse than the local control rates for those with central tumors 82% (SE 8%), distal extremity 80% (SE 8%), or proximal extremity 69% (SE 9%) (p=0.023). However, quality of radiotherapy correlated with outcome. Patients who had appropriate radiotherapy had a 5-year local control of 80% (SE 7%), while those with minor deviations had 5-year local control of 48% (SE 14%), and those with major deviations had a local control of only 16% (SE 15%) (p=0.005). The local failure was within an irradiated volume in 62% of patients, outside the irradiated volume in 24% of cases, while the precise location could not be determined in the remaining 14%. CONCLUSIONS As most failures in Ewings sarcoma are systemic, improved EFS requires more effective systemic chemotherapy. Adequate IF radiotherapy requires treatment to appropriate volumes as defined by MRI imaging and full radiation doses. Pretreatment review of radiologic images with a musculoskeletal radiologist to determine appropriate tumor volumes, as well as use of conformal radiotherapy techniques are important for improved outcome.


Cancer | 1992

Clonal chromosomal abnormalities in desmoid tumors. Implications for histopathogenesis.

Julia A. Bridge; Chandrika Sreekantaiah; Barbara J. Mouron; James R. Neff; Avery A. Sandberg; Sandra R. Wolman

Desmoid tumors (aggressive fibromatosis) are regarded as lesions of uncertain histopathogenesis. Cytogenetic analyses of 26 desmoid tumor specimens from abdominal or extraabdominal sites of 22 patients with or without Gardners syndrome (GS) showed clonal karyotypic abnormalities in 7 cases, random abnormalities in 14 cases, and striking telomeric fusion in 5 cases. Loss of chromosome Y, a reported feature of fibromatosis in penile and palmar locations, was detected as a clonal aberration in two patients. Additionally, involvement of 5q was observed in six patients, two of whom had GS. Clonal interstitial deletions of 5q were observed in three patients, one with and two without GS. These findings confirm a clonal and probable neoplastic origin for desmoid tumor and suggest that abnormalities of the Y chromosome and 5q may be important in the genesis of this neoplasm.


Cancer Genetics and Cytogenetics | 1990

Cytogenetic analysis of dermatofibrosarcoma protuberans

Julia A. Bridge; James R. Neff; Avery A. Sandberg

A case of dermatofibrosarcoma protuberans that occurred in an old burn scar over the anterior chest wall of a 46-year-old man is reported. Cytogenetic analysis of the tumor cells showed the presence of two abnormal clones: 47,XY, +8 and 48,XY, +8, +r.


International Journal of Radiation Oncology Biology Physics | 1985

Local recurrence, rate and sites of metastases, and time to relapse as a function of treatment regimen, size of primary and surgical history in 62 patients presenting with non-metastatic Ewing's sarcoma of the pelvic bones

Richard G. Evans; Mark E. Nesbit; Fred Askin; Omer Burgert; Ayten Cangir; Mary A. Foulkes; Gehan Ea; Louis A. Gilula; John M. Kissane; John Makley; James R. Neff; Carlos A. Perez; Douglas J. Pritchard; Melvin Tefft; Patrick R. M. Thomas; Teresa J. Vietti

This report reviews the experience of 62 patients who presented between 1972 and 1978 with non-metastatic Ewings sarcoma of the pelvis and were entered on IESS I. Seventeen patients (27%) developed a local recurrence, 38 patients (61%) demonstrated metastases and 21 (34%) neither. In the dose range 4000 rad to 6000 rad no dose response could be detected for local control of tumor. Forty-six patients (74%) had a biopsy or exploratory surgery only, 5 patients (8%) had an incomplete resection and 11 patients (18%) had a complete resection of their tumor. In the 46 patients having a biopsy only, 13 developed a local recurrence (28%) as compared to 2 of 11 patients undergoing a complete resection (18%). The most common sites for metastases were lung in 19 patients (31%) and bone in 23 patients (37%). No significant difference was noted in the frequency of overall metastases or metastases to any site between those patients receiving one of the three treatment regimens used in IESS I: VAC and Adriamycin (regimen I), VAC alone (regimen II) and VAC plus bilateral pulmonary irradiation (regimen III). At a median follow-up of 135 weeks no significant difference in median survival could be detected in patients with pelvic primaries between regimens I, II and III. The mean diameter of the pelvic primaries was comparable to the nonpelvic, however, one half of the pelvic cases were in the range 10-15 cm. The median time to relapse of the 241 non-pelvic patients on IESS I was 222 weeks as contrasted with the median time to relapse of 92 weeks in the 62 pelvic patients on the same study (p = 0.002). The possible reasons for the poor prognosis of pelvic primary patients are discussed together with treatment policies that might improve the survival of this group of patients.


Cancer Genetics and Cytogenetics | 1991

Cytogenetic findings in clear cell sarcoma of tendons and aponeuroses: Malignant melanoma of soft parts

Julia A. Bridge; Chandrika Sreekantaiah; James R. Neff; Avery A. Sandberg

Cytogenetic analyses of clear cell sarcomas from two patients are reported. Clonal numerical and structural abnormalities were detected in both specimens, with specific involvement of chromosomes 2 and 22 in each.


Cancer | 1990

Cytogenetic findings and biologic behavior of giant cell tumors of bone

Julia A. Bridge; James R. Neff; Paramjit Bhatia; Warren G. Sanger; Mark D. Murphey

Giant cell tumor of bone is a benign but often aggressive lesion with a distinct tendency toward local recurrence and, rarely, malignant transformation. Over a 3‐year period, 20 giant cell tumors from 14 different patients were cytogenetically characterized. Random chromosomal abnormalities were detected in 14 of the 20 specimens and clonal chromosomal abnormalities were detected in six. An unusual anomaly, telomeric fusion, was the most striking random chromosomal abnormality detected. A comparison of the presence or absence of cytogenetic aberrations and the clinical behavior of these neoplasms was studied as well as a comparison of the aberrations in the initial specimen with those in subsequent specimens. Chromosomal abnormalities were detected in all but one of the ten tumors shown to be locally aggressive, recurrent, or metastatic. (The abnormalities observed in five of these tumors were clonal.) There were no chromosomal abnormalities present in three of four tumors that behaved in an innocent fashion. These findings support the presence of chromosomal abnormalities in giant cell tumors (telomeric fusion in particular) and suggest that cytogenetic analysis may be useful in predicting the biologic behavior of these neoplasms.


Medical and Pediatric Oncology | 1998

Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: A Pediatric Oncology Group Study

Charles B. Pratt; Harold M. Maurer; Peter W. Gieser; Arnold M. Salzberg; Bhaskar N. Rao; David M. Parham; Patrick R.M. Thomas; Robert B. Marcus; Alan Cantor; Terry Pick; Daniel M. Green; James R. Neff; Jesse J. Jenkins

BACKGROUND The objectives of this study were to compare vincristine/actinomycin D/cyclophosphamide/adriamycin (VACA) with VACA/plus imidazole carboxamide (DTIC) (VACAD) therapy in regards to complete/partial response and event free survival rates in children and adolescents with metastatic non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) or previously chemotherapy-naive recurrent NRSTS or locally persistent gross residual tumor after surgery and radiation therapy. PROCEDURES Between 1986 and March 1994, 75 patients entered this randomized study comparing VACA and VACAD, given at 3 week intervals. Sixty-one patients were considered eligible and received chemotherapy and radiation therapy to the primary tumor and areas of metastases. Thirty-six patients had regional unresected (Group III) disease, and 25 had metastatic disease (Group IV) at time of accession. Thirty-six patients received VACA (11 were not randomized), and 25 received VACAD. RESULTS With a median follow-up of greater than 4 years, overall and event-free survival for all eligible patients are 30.6% and 18.4% respectively (S.E: 9.5% and 6.8%). There was insufficient evidence that DTIC offered any advantage to event free survival, but there was evidence for better outcome for patients in Group III disease in comparison to patients with Group IV disease, and for patients with a Grade 1 and 2 histology in comparison to Grade 3 lesions. CONCLUSIONS Combination chemotherapy with VACA and VACAD were insufficient to prevent recurrent or progressive disease in children and adolescents with high stage NRSTS. The use of vincristine/ifosfamide/doxorubicin with cytokine support is under study.


Cancer Genetics and Cytogenetics | 1989

Translocations involving chromosomes 2 and 13 in benign and malignant cartilaginous neoplasms

Julia A. Bridge; Warren G. Sanger; James R. Neff

Cytogenetic analysis of a chrondromyxoid fibroma of bone and an extraskeletal myxoid chondrosarcoma revealed clonal chromosomal rearrangements involving chromosomes 2 and 13. The significance of these findings in these neoplasms of cartilaginous origin, one benign and one malignant, is discussed.


Cancer Genetics and Cytogenetics | 1987

Cytogenetic findings in malignant fibrous histiocytoma

Julia A. Bridge; Warren G. Sanger; Barbara Shaffer; James R. Neff

The cytogenetic findings of two malignant fibrous histiocytomas from two unrelated patients are discussed. Both tumors were characterized by trisomy 7.


Cancer Genetics and Cytogenetics | 1991

Clonal chromosomal abnormalities in hemangiopericytoma.

Chandrika Sreekantaiah; Julia A. Bridge; Uma N.M. Rao; James R. Neff; Avery A. Sandberg

We report the cytogenetic findings in nine hemangiopericytomas studied after short-term culture. Clonal chromosome abnormalities were present in four cases. One case had a simple translocation (12;19)(q13;q13.3) as the sole abnormality whereas complex and multiple chromosomal abnormalities involving almost all chromosomes in the complement characterized tumors from the three other cases.

Collaboration


Dive into the James R. Neff's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Warren G. Sanger

University of Nebraska Medical Center

View shared research outputs
Top Co-Authors

Avatar

A A De Smet

University of Wisconsin-Madison

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Elizabeth I. Thompson

St. Jude Children's Research Hospital

View shared research outputs
Top Co-Authors

Avatar

Fran Laurie

Quality Assurance Review Center

View shared research outputs
Top Co-Authors

Avatar

John T. Manning

University of Texas MD Anderson Cancer Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge